10-Q: CareView Narrows Losses, Boosts Cash Amid Growth

CareView Communications reports significantly reduced net losses and increased cash from operations for Q3 2025, despite ongoing going concern doubts and internal control weaknesses.

Summary

• Net loss for the three months ended September 30, 2025, decreased by 37.8% to $914,000, compared to $1,470,000 in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, decreased by 32.7% to $2,423,000, compared to $3,600,000 in the same period of 2024.
• Total revenues for the three months ended September 30, 2025, increased by $133,000 (6.9%) to $2,065,000, driven by recurring annual software revenue.
• Total revenues for the nine months ended September 30, 2025, increased by $574,000 (9.4%) to $6,683,000.
• Operating expenses decreased by 16% for the three-month period and 8.1% for the nine-month period, primarily due to layoffs, renegotiated insurance and rent, and managed advertising/marketing.
• Cash balance increased to $1,731,276 as of September 30, 2025, from $759,266 at December 31, 2024.
• Net cash flows provided by operating activities significantly improved to $1,033,269 for the nine months ended September 30, 2025, compared to $392,966 in the prior year period.
• The company continues to operate with a working capital deficit of $42,789,653 and an accumulated deficit of $215,009,822 as of September 30, 2025.
• The maturity date for the PDL Credit Agreement was extended for the fourth time in the past year, now to December 31, 2025, and is accounted for as a troubled debt restructuring.

Sentiment

Score: 4

Explanation: While the company showed significant improvements in reducing net losses and increasing cash from operations, the persistent 'going concern' warning, substantial working capital deficit, and material weakness in internal controls indicate a precarious financial position. The repeated debt maturity extensions also signal ongoing financial challenges, tempering the positive operational trends.

Positives

• Net loss significantly decreased by 37.8% for the quarter and 32.7% for the nine-month period, indicating improved financial performance.
• Revenue increased by 6.9% for the quarter and 9.4% for the nine-month period, primarily driven by recurring annual software revenue.
• Operating expenses decreased by 16% for the quarter and 8.1% for the nine-month period, reflecting successful cost management efforts including layoffs and renegotiated contracts.
• Net cash provided by operating activities substantially increased to $1,033,269 for the nine-month period, demonstrating improved operational cash generation.
• Cash balance nearly doubled to $1,731,276, enhancing immediate liquidity.
• The company continues to expand its market reach through partnerships with Decisive Point Consulting Group (VA hospitals), Shore Systems and Solutions (IDIQ contract), GSA Multiple Award Schedule, HealthTrust, Premier, and Vizient GPOs.
• CareView received an Innovative Technology designation from Vizient in Q4 2022, highlighting its advanced patient safety solutions.

Negatives

• The company continues to report net losses and has an accumulated deficit of $215,009,822 as of September 30, 2025.
• A significant working capital deficit of $42,789,653 persists as of September 30, 2025.
• The company's ability to continue as a going concern is in substantial doubt without additional funding.
• Disclosure controls and procedures were deemed ineffective as of September 30, 2025, due to a material weakness in internal control over financial reporting of technical accounting.
• The PDL Credit Agreement's maturity date has been repeatedly extended, with the latest extension to December 31, 2025, and is accounted for as a troubled debt restructuring, indicating ongoing financial strain.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to net losses and a significant working capital deficit.
• Material weakness in internal control over financial reporting of technical accounting, which could lead to material misstatements in financial statements.
• Dependence on obtaining adequate financing to fulfill growth and operating activities and generate sufficient revenue to support the cost structure.
• Risks inherent to healthcare technology companies, including dependence on key individuals, uncertainty of product development, and successful protection of intellectual property.
• Susceptibility to infringement on the proprietary rights of others.
• The company's debt instruments, particularly the PDL Credit Agreement, are subject to repeated extensions and are classified as troubled debt restructurings, indicating financial instability.

Future Outlook

Management plans to continue funding operations through increased sales volumes and by raising additional capital from debt or equity securities or loans. The company is assessing the potential effects of new accounting standards on its financial statements and considering early adoption for some. The company aims to improve its financial position and achieve profitable operations, which is dependent on future events and successful capital raising.

Management Comments

• Management believes the condensed consolidated financial statements fairly present, in all material respects, the financial position, results of operations, and cash flows.
• Management is responsible for establishing and maintaining disclosure controls and procedures and internal control over financial reporting.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to a material weakness in internal control over financial reporting of technical accounting.
• Management is implementing a remediation plan to address material weaknesses, including employing additional qualified accounting personnel, enhancing documentation, providing training, automating controls, and engaging third-party experts.
• Management will look to continue funding operations by increased sales volumes and raising additional capital from sources such as sales of its debt or equity securities or loans to meet operating cash requirements.

Industry Context

The company operates in the healthcare technology sector, providing patient video monitoring solutions. Its focus on remote patient monitoring, virtual nursing workflows, and patient safety systems aligns with broader industry trends driven by increasing demands for care, staffing shortages, and the need for operational cost reduction in hospitals and long-term care facilities. The expansion into the skilled nursing home and assisted living markets with CareView Connect addresses a significant and growing demographic need for quality of life monitoring and alert management.

Comparison to Industry Standards

• The company's claims of reducing patient falls by 80% and sitter costs by over 65% with its Patient Safety System are significant improvements, potentially outperforming traditional patient observation methods. Specific comparable companies or projects are not detailed in the filing, but these metrics suggest strong performance relative to industry averages for fall prevention and cost savings.
• The company's extensive patent portfolio (40 patents) indicates a strong commitment to innovation and intellectual property protection, which is a competitive advantage in the healthcare technology space.
• The company's partnerships with major Group Purchasing Organizations (GPOs) like HealthTrust, Premier, and Vizient, as well as government contractors like Decisive Point Consulting Group and Shore Systems and Solutions, position it well for market penetration within the U.S. healthcare system, including VA and DOD facilities. This broad market access is a key industry standard for scaling healthcare solutions.

Corporate Governance

Related Party Transactions

• Notes payable related parties of $700,000 as of September 30, 2025.
• Steven G. Johnson, President and Chief Executive Officer, and Dr. James R. Higgins, a director, are parties to the amendments of the Credit Agreement with PDL BioPharma, Inc.

Stakeholder Impact

• **Shareholders**: Potential for dilution if equity is issued to raise capital; continued uncertainty regarding the company's going concern status and long-term viability. Improved financial performance (reduced losses, increased cash from operations) could be seen as a positive trend.
• **Creditors (PDL BioPharma, Inc.)**: Repeated extensions of debt maturity and troubled debt restructuring classification indicate ongoing risk and reliance on forbearance.
• **Employees**: Layoffs contributed to reduced human resource costs, indicating potential job insecurity. The remediation plan for internal controls includes employing additional accounting personnel, which could create new opportunities.
• **Customers (Hospitals/Healthcare Facilities)**: Continued product development and market expansion through GPOs suggest ongoing commitment to service and innovation. The sales-based model offers flexibility in equipment acquisition.
• **Suppliers**: Potential impact from new inventory orders and capital expenditure controls.

Next Steps

• Continue efforts to increase sales volumes and expand market reach.
• Pursue additional capital raising through debt or equity securities or loans.
• Implement the remediation plan to address the material weakness in internal control over financial reporting.
• Assess the impact and consider early adoption of recently issued accounting pronouncements (e.g., ASU 2025-06 for internal-use software).

Key Dates

Recommendation

While CareView Communications demonstrated significant improvements in reducing net losses and generating positive cash flow from operations, the persistent 'going concern' warning and a substantial working capital deficit present considerable risks. The repeated extensions of the PDL Credit Agreement, classified as troubled debt restructurings, highlight ongoing financial fragility. The material weakness in internal controls also adds a layer of uncertainty regarding financial reporting reliability. Given these mixed signals—positive operational trends against severe financial and governance risks—a 'hold' recommendation is appropriate. Investors should monitor the company's progress on its remediation plan, capital raising efforts, and ability to sustain operational improvements before considering further investment.

Keywords

Patient Safety System, Healthcare Technology, Remote Patient Monitoring, Virtual Nursing, CareView Connect, SEC Filing, 10-Q, Financial Results, Going Concern, Internal Controls, Medical Devices, Software as a Service, Hospital Solutions